Skip to main content

Table 2 Association between frequency of programmed death ligand 1 (PD-L1)-expressing neutrophils and clinical features

From: PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus

Clinical features (number)

 

Case

PD-L1-expressing neutrophils (%)

P

Cutaneous manifestations (71)

Yes

12

44.18 ± 8.156

0.0046

No

59

20.55 ± 2.419

Arthritis (71)

Yes

11

35.29 ± 6.522

0.0805

No

60

22.59 ± 2.822

Alopecia (71)

Yes

4

30.93 ± 7.235

0.5580

No

67

24.18 ± 2.755

Fever (71)

Yes

5

47.60 ± 9.637

0.0148

No

66

22.82 ± 2.629

Oral ulcer (71)

Yes

3

41.80 ± 9.211

0.1702

No

68

23.80 ± 2.688

Raynaud's phenomenon (71)

Yes

5

42.90 ± 10.20

0.0543

No

66

23.17 ± 2.665

Serositis (71)

Yes

3

25.37 ± 2.978

0.9492

No

68

24.53 ± 2.744

Renal involvement (71)

Yes

27

21.71 ± 4.256

0.3998

No

44

26.31 ± 3.355

Pyuria (71)

Yes

13

15.28 ± 5.781

0.0948

No

58

26.64 ± 2.899

Hematuria (71)

Yes

6

43.33 ± 12.92

0.029

No

65

22.83 ± 2.550

Proteinuria (71)

Yes

16

22.41 ± 5.084

0.6627

No

55

25.19 ± 3.074

Erythrocytopenia (71)*

Yes

20

36.06 ± 5.64

0.0161

No

51

21.90 ± 2.837

Leucopenia (59)*

Yes

8

40.30 ± 10.01

0.0232

No

51

21.75 ± 2.751

Thrombocytopenia (68)*

Yes

5

42.34 ± 11.31

0.0337

No

63

21.84 ± 2.517

Anemia (75)

Yes

19

37.47 ± 5.711

0.0041

No

56

20.82 ± 2.648

  1. The t test was used when the data distribution was confirmed as normal, otherwise, the nonparametric Mann–Whitney test was used to analyze the data. P <0.05 was considered as statistically significant. *SLE patients with increased cell counts of RBC, WBC and PLT were excluded